دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Acute and chronic heart failure: exciting therapeutic perspectives
Filippo Crea
doi : 10.1093/eurheartj/ehac767
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 1–4
Interview with Nobel Laureate Gregg Semenza: an inspiring story for young researchers
Stefania Angela Di Fusco, Furio Colivicchi
doi : 10.1093/eurheartj/ehac591
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 5–6
Virtual hospitals and digital doctors: how far are we from the CardioVerse?
Ioannis Skalidis, Stephane Fournier, Emmanouil Skalidis, Niccolo Maurizi
doi : 10.1093/eurheartj/ehac603
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 7–9
The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology
Liam S Couch, Teresa López-Fernández, Alexander R Lyon
doi : 10.1093/eurheartj/ehac666
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 10–11
Solid evidence that very few muscle symptoms are due to statin therapy
Giovanna Liuzzo, Carlo Patrono
doi : 10.1093/eurheartj/ehac620
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 12–13
Iron deficiency and cardiovascular disease
Gianluigi Savarese, Stephan von Haehling, Javed Butler, John G F Cleland, Piotr Ponikowski, Stefan D Anker
doi : 10.1093/eurheartj/ehac569
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 14–27
Iron deficiency (ID) is common in patients with cardiovascular disease. Up to 60% of patients with coronary artery disease, and an even higher proportion of those with heart failure (HF) or pulmonary hypertension have ID; the evidence for cerebrovascular disease, aortic stenosis and atrial fibrillation is less robust.
Valvular heart disease: shifting the focus to the myocardium
Nina Ajmone Marsan, Victoria Delgado, Dipan J Shah, Patricia Pellikka, Jeroen J Bax, Thomas Treibel, João L Cavalcante
doi : 10.1093/eurheartj/ehac504
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 28–40
Adverse cardiac remodelling is the main determinant of patient prognosis in degenerative valvular heart disease (VHD). However, to give an indication for valvular intervention, current guidelines include parameters of cardiac chamber dilatation or function which are subject to variability, do not directly reflect myocardial structural changes, and, more importantly, seem to be not sensitive enough in depicting early signs of myocardial dysfunction before irreversible myocardial damage has occurred.
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Jan Biegus, Adriaan A Voors, Sean P Collins, Mikhail N Kosiborod, John R Teerlink, Christiane E Angermann, Jasper Tromp, Joao Pedro Ferreira, Michael E Nassif, Mitchell A Psotka, Martina Brueckmann, Afshin Salsali, Jonathan P Blatchford, Piotr Ponikowski
doi : 10.1093/eurheartj/ehac530
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 41–50
Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in the EMPULSE trial (NCT0415775) were evaluated.
Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?
Alexandre Mebazaa, Alain Cohen Solal, Paolo C Colombo
doi : 10.1093/eurheartj/ehac680
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 51–53
Survival of patients with congenital ventricular septal defect
Filip Eckerström, Camilla Nyboe, Marie Maagaard, Andrew Redington, Vibeke Elisabeth Hjortdal
doi : 10.1093/eurheartj/ehac618
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 54–61
The long-term survival of patients with isolated congenital ventricular septal defect (VSD) is not well described. The aim of this study was to describe the survival of a national cohort of patients with VSD compared with the general population.
Half a century of experience with congenital heart disease: what have we learned about ventricular septal defects?
Anne Marie Valente, Michael D Freed
doi : 10.1093/eurheartj/ehac657
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 62–63
Fit for the future: empowering clinical trials with digital technology
Dipak Kotecha, Adam D DeVore, Folkert W Asselbergs
doi : 10.1093/eurheartj/ehac650
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 64–67
More costs than benefits from screening for cardiovascular disease with computed tomography in the DANCAVAS study
Niels Holmark Andersen, Torben Jørgensen, John Brandt Brodersen
doi : 10.1093/eurheartj/ehac634
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Pages 68–69
Incidental detection in the DANCAVAS trial was limited by design and did not bias the cost effectiveness conclusion
Rikke Søgaard, Axel Diederichsen, Jes Lindholt
doi : 10.1093/eurheartj/ehac646
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Page 70
Emoji-like structure in the right atrium: identified as blood cyst and removed by interventional venous drainage cannula
Assem Aweimer, Leif I Bösche, Aydan Ewers, Ibrahim El-Battrawy, Andreas Mügge
doi : 10.1093/eurheartj/ehac567
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Page 71
Pulmonary artery bone cement embolization resulting from percutaneous vertebroplasty
Leizhi Ku, Hang Lv, Xiaojing Ma
doi : 10.1093/eurheartj/ehac588
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Page 72
Erratum to: Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis
doi : 10.1093/eurheartj/ehac628
European Heart Journal, Volume 44, Issue 1, 1 January 2023, Page 27
Erratum to: Sutton’s law and dietary Na+/K+ intake in cardiovascular disease
